Bacainn Therapeutics Reports Positive Topline Results from Phase 1 Study of BT051, a Novel Therapeutic Approach to Treat Inflammatory Diseases Such As Ulcerative Colitis
Date Posted: Thursday, December 03, 2020CONCORD, Mass. — Bacainn Therapeutics, Inc., a Company developing novel therapies to address uncontrolled inflammation, today announced thesuccessful completion of the company’s Phase 1, first-in-human clinical trial of BT051, a novel, orally administered, gut-selective inhibitor of migration and activation of neutrophils.